18
Participants
Start Date
August 31, 2013
Primary Completion Date
October 31, 2013
Study Completion Date
October 31, 2013
Oxycodone
One capsule of 40 mg PF-00345439 Formulation X, single dose, under fasting conditions
Oxycodone
One capsule of 40 mg PF-00345439 Formulation K, single dose, under fasting conditions
Oxycodone
One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
Pfizer Investigational Site, Baltimore
Lead Sponsor
Pain Therapeutics
INDUSTRY